Inhibrx Biosciences Q4 net loss narrows as expenses fall
Overview
Biopharmaceutical developer's Q4 net loss narrowed yr/yr as operating expenses declined
Company's R&D and G&A expenses fell due to lower clinical trial and legal costs
Company ended 2025 with $124.2 mln cash, added $75 mln loan in March 2026
Result Drivers
LOWER CLINICAL TRIAL COSTS - Co said Q4 R&D expenses fell due to reduced clinical trial costs for ozekibart as enrollment neared completion
REDUCED CONTRACT MANUFACTURING - Co attributed lower R&D expenses to decreased contract manufacturing costs for ozekibart and INBRX-106
CONCLUDED LEGAL PROCEEDINGS - Co said Q4 G&A expenses dropped as legal proceedings ended, removing prior period costs
Company press release: ID:nPn7j3qZ1a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 EPS | Miss | -$2.11 | -$2.08 (1 Analyst) |
Q4 Net Income | Miss | -$32.83 mln | -$32.22 mln (1 Analyst) |
Q4 Operating Income | Beat | -$30.92 mln | -$34.15 mln (1 Analyst) |
Q4 Operating Expenses |
| $30.92 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "hold"
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
